- |||||||||| Journal: Personalized character of toxic effects through mass nonlethal poisoning by phenazepam and other psychoactive substances (Pubmed Central) - Feb 18, 2024
The phenazepam concentration in the blood was in the range of 109.75-786.50 ng/ml, in the urine - 8.97-101.28 ng/ml. The pharmacokinetic and toxicokinetic characteristics of toxicants as well as additional factors characterizing the phenotype of the sufferer in addition to drug's content in the biological material must be taken into account to determine the toxicity level of phenazepam against the background of combined action with other psychoactive substances.
- |||||||||| Review, Journal: Global occurrence and aquatic hazards of antipsychotics in sewage influents, effluent discharges and surface waters. (Pubmed Central) - Jan 17, 2023
In contrast, we observed elevated aquatic hazards for chlorpromazine (30.5%), aripiprazole (37.5%), and perphenazine (68.7%) in effluent discharges, and for chlorprothixene (35.4%) and flupentixol (98.8%) in surface waters. Elevated aquatic hazards for relatively understudied antipsychotics were identified, which highlight important data gaps for future environmental chemistry and toxicology research.
- |||||||||| chlorprothixene / Generic mfg., olanzapine / Generic mfg.
Journal: Association of In Utero Antipsychotic Medication Exposure With Risk of Congenital Malformations in Nordic Countries and the US. (Pubmed Central) - Dec 9, 2022
In this study, considering the evidence from primary and sensitivity analyses and inevitable statistical noise for very rare exposure-outcome combinations, in utero antipsychotic exposure generally was not meaningfully associated with an increased risk of malformations. The observed increased risks of oral clefts associated with olanzapine, gastroschisis, and other specific brain anomalies with atypical antipsychotics and cardiac malformations with chlorprothixene requires confirmation as evidence continues to accumulate.
- |||||||||| lithium carbonate ER / Generic mfg.
Journal, HEOR: Comparative effectiveness of mood stabilizers and antipsychotics in the prevention of hospitalization after lithium discontinuation in bipolar disorder. (Pubmed Central) - Aug 18, 2022
Of antipsychotic monotherapies, the use of long-acting injectable (LAI) antipsychotics (HR = 0.48, 95% CI = 0.26 - 0.88) and chlorprothixene (HR = 0.62, 95% CI = 0.44 - 0.88) were associated with lower risk and the use of quetiapine (HR = 1.26, 95% CI = 1.07 - 1.48) and oral olanzapine (HR = 1.23, 95% CI = 1.01 - 1.49) with higher risk of psychiatric hospitalizations than nonuse of antipsychotics...The results suggest that antipsychotic LAIs are especially effective in the prevention of psychiatric hospitalizations after lithium discontinuation. The need to alter used medications may be the lowest when lithium is restarted.
- |||||||||| chlorprothixene / Generic mfg.
Journal, Adverse events: Use of chlorprothixene and the risk of diabetes and major adverse cardiovascular events: a nation-wide cohort study. (Pubmed Central) - Apr 5, 2022
Cumulative dose of chlorprothixene ≥6000mg was associated with increased risk of diabetes (OR:1.15-1.63;test for trend:p<0.001), whereas cumulative dose of chlorprothixene ≥1500mg was associated with increased risk of MACE (OR:1.10-1.85;test for trend:p<0.001). In conclusion, low-dose chlorprothixene use is associated with increased risk of cardiometabolic adverse events compared to low-dose quetiapine use.
- |||||||||| trifluoperazine / Generic mfg.
Journal, IO biomarker: Repurposing of Antipsychotic Trifluoperazine for Treating Brain Metastasis, Lung Metastasis and Bone Metastasis of Melanoma by Disrupting Autophagy Flux. (Pubmed Central) - Nov 21, 2021
Moreover, the colocalization of LC3 with lysosomal-associated membrane protein 1 (LAMP1), a lysosome marker, was also suppressed after TFP treatment, suggesting that TFP might block the fusion of autophagosomes with lysosomes, which led to autophagosome accumulation. Taken together, our data highlight the potential of repurposing TFP as a new adjuvant drug for treating melanoma patients with brain, lung, and bone metastases.
- |||||||||| methylphenidate tablet / Generic mfg., risperidone / Generic mfg.
Review, Journal: Hair analysis of antidepressants and antipsychotics - overview of quantitative data. (Pubmed Central) - Apr 1, 2021
A harmonization on the investigated hair lengths as well as on the extraction protocol would be of favor to achieve better comparability. Although hair analysis research focused mainly on drugs abuse, contribution of more data on antidepressants and antipsychotics would help to gain better knowledge and assistance for other forensic investigators.
- |||||||||| chlorprothixene / Generic mfg., levomepromazine / Generic mfg.
Journal: Drug Repurposing Screen for Compounds Inhibiting the Cytopathic Effect of SARS-CoV-2. (Pubmed Central) - Mar 13, 2021
These three compounds have not been previously reported to have anti-SARS-CoV-2 activities, although their antiviral activities against SARS-CoV and Ebola virus have been reported. These results demonstrate that this comprehensive data set is a useful resource for drug repurposing efforts, including design of new drug combinations for clinical trials for SARS-CoV-2.
- |||||||||| chlorprothixene / Generic mfg., chlorpromazine / Generic mfg.
Preclinical, Journal: Acepromazine and Chlorpromazine as Pharmaceutical-grade Alternatives to Chlorprothixene for Pupillary Light Reflex Imaging in Mice. (Pubmed Central) - Jan 26, 2021
Full recovery (as defined by purposeful movement,response to tactile stimuli, and full alertness) was not regularly achieved in any sedative group. In conclusion, at the doses tested, acepromazine and chlorpromazine are suitable pharmaceutical-grade alternatives to chlorprothixene for pupil imaging and conceivably other in vivo photoresponse measurements; however, given the lack of full recovery, lower dosages should be investigated further for use in survival procedures.
- |||||||||| methadone / Generic mfg.
Clinical, Journal: Optimisation of methadone treatment in a group of patients on a mephedrone binge and dependent on many psychoactive substances. (Pubmed Central) - Dec 18, 2020
The most optimal therapeutic effect is characteristic for the intake of methadone with thiazolidine carboxylic acid, namely 95% of people using this type of treatment were hospitalised once (p < .001). Therapy with methadone and thiazolidine carboxylic acid seems to be the most optimal therapy for patients taking mephedrone.Key pointsThe number of hospitalisations of patients receiving mephedrone on a regular basis grows from year to year.The multiple use of poly-pharmacotherapy increased in a group of patients on a mephedrone binge.There is a statistically significant correlation between the number of hospitalisations of patients on a mephedrone binge and the total number of drugs taken together with methadone.Administration of methadone with thiazolidine carboxylic acid was the most effective therapy for patients regularly combining mephedrone with at least two other psychoactive substances.
- |||||||||| risperidone / Generic mfg., Egis, chlorprothixene / Generic mfg., haloperidol / Generic mfg.
Journal: Electromembrane extraction of chlorprothixene, haloperidol and risperidone from whole blood and urine. (Pubmed Central) - Nov 6, 2020
The limit of detection (LOD) and accuracy for all the targets ranged from 0.2-0.6 ng mL and 102%-110%, respectively, and the repeatability at low (1 ng mL), medium (10 ng mL) and high (200 ng mL) concentration was ≤ 12% (RSD). Finally, the validated approach was successfully used to determine chlorprothixene, risperidone and haloperidol in whole blood and urine from rats, which were treated with chlorprothixene, risperidone and haloperidol at low therapeutic dose, respectively.
- |||||||||| Enrollment change, Trial termination, Trial primary completion date, Adverse events: Pharmacovigilance in Gerontopsychiatric Patients (clinicaltrials.gov) - Oct 19, 2017
P3, N=407, Terminated,
Reasons for and consequences of increased antipsychotic use that lasts shorter periods of time requires further study. N=2000 --> 407 | Recruiting --> Terminated | Trial primary completion date: Feb 2017 --> Jun 2017
|
